ESR1 and breast cancer: The receptor, however, also influences the growth of HER2+ ER– BC cells in non-genomic way, since in these cells, inhibition of AR by Enzalutamide decreases the HER2 phosphorylation without affecting the total level of HER2 or HER3, and treatment of cells with a combination of enzalutamide and trastuzumab, an approved HER2 target drug, potentiates the inhibitory effect on cell growth due to a single inhibiting drug (49).